Novel D: -erythro N-octanoyl sphingosine analogs as chemo- and endocrine-resistant breast cancer therapeutics
- PMID: 20155475
- DOI: 10.1007/s00280-009-1233-0
Novel D: -erythro N-octanoyl sphingosine analogs as chemo- and endocrine-resistant breast cancer therapeutics
Abstract
Purpose: Resistance to endocrine and chemotherapies remains the primary cause of breast cancer treatment failure. We have synthesized four novel D: -erythro N-octanoyl sphingosine analogs and catalogued their activity in drug-sensitive (MCF-7), endocrine-resistant (MDA-MB-231) and chemoresistant (MCF-7TN-R) breast cancer cells.
Methods: 3-(4,5-Dimethylthiazol-2-Yl)-2,5-diphenyltetrazolium bromide (MTT) assay was used to determine cell viability; colony assay was performed to determine effects on clonogenic survival and (1)H NMR, (13)C NMR, HPLC spectra and elemental analytical data analyses were used to determine analog identity and purity.
Results: All four analogs inhibited both viability and clonogenic survival, with analog C exhibiting a log-fold improvement in anti-survival activity compared to the parent compound.
Conclusion: With resistance to current breast cancer chemotherapies on the rise, the development of novel therapeutic _targets is of growing importance. Our results show that lipid analogs have therapeutic potential in treating chemo- and endocrine-resistant breast cancer.
Similar articles
-
Design, synthesis, and biological activity of a family of novel ceramide analogues in chemoresistant breast cancer cells.J Med Chem. 2009 Sep 24;52(18):5748-52. doi: 10.1021/jm9009668. J Med Chem. 2009. PMID: 19694470
-
Novel ceramide analogs as potential chemotherapeutic agents in breast cancer.J Pharmacol Exp Ther. 2004 May;309(2):523-32. doi: 10.1124/jpet.103.062760. Epub 2004 Jan 23. J Pharmacol Exp Ther. 2004. PMID: 14742741
-
Novel anti-viability ceramide analogs: design, synthesis, and structure-activity relationship studies of substituted (S)-2-(benzylideneamino)-3-hydroxy-N-tetradecylpropanamides.Bioorg Med Chem. 2010 Jul 15;18(14):5316-22. doi: 10.1016/j.bmc.2010.05.044. Epub 2010 Jun 8. Bioorg Med Chem. 2010. PMID: 20639111
-
Anti-proliferative effects of the novel ceramide analog (S)-2-(benzylideneamino)-3-hydroxy-N-tetrade-cylpropanamide in chemoresistant cancer.Bioorg Med Chem Lett. 2012 Apr 1;22(7):2624-8. doi: 10.1016/j.bmcl.2012.01.087. Epub 2012 Jan 28. Bioorg Med Chem Lett. 2012. PMID: 22366655
-
Design, synthesis and biological activity of cell-penetrating peptide-modified octreotide analogs.J Pept Sci. 2010 Feb;16(2):105-9. doi: 10.1002/psc.1205. J Pept Sci. 2010. PMID: 20014325
Cited by
-
Inhibition of p38-MAPK alters SRC coactivation and estrogen receptor phosphorylation.Cancer Biol Ther. 2012 Sep;13(11):1026-33. doi: 10.4161/cbt.20992. Epub 2012 Jul 24. Cancer Biol Ther. 2012. PMID: 22825349 Free PMC article.
-
Inhibition of breast tumor growth in mice after treatment with ceramide analog 315.Anticancer Drugs. 2018 Oct;29(9):898-903. doi: 10.1097/CAD.0000000000000675. Anticancer Drugs. 2018. PMID: 30044300 Free PMC article.
-
3-Ketone-4,6-diene ceramide analogs exclusively induce apoptosis in chemo-resistant cancer cells.Bioorg Med Chem. 2014 Feb 15;22(4):1412-20. doi: 10.1016/j.bmc.2013.12.065. Epub 2014 Jan 8. Bioorg Med Chem. 2014. PMID: 24457089 Free PMC article.
-
Antiestrogenic activity of flavonoid phytochemicals mediated via the c-Jun N-terminal protein kinase pathway. Cell-type specific regulation of estrogen receptor alpha.J Steroid Biochem Mol Biol. 2012 Oct;132(1-2):186-93. doi: 10.1016/j.jsbmb.2012.05.004. Epub 2012 May 24. J Steroid Biochem Mol Biol. 2012. PMID: 22634477 Free PMC article.
-
Anti-cancer effectiveness of a novel ceramide analog on chemo-sensitive and chemo-resistant breast cancers.Anticancer Drugs. 2024 Jan 1;35(1):12-21. doi: 10.1097/CAD.0000000000001536. Epub 2023 Aug 15. Anticancer Drugs. 2024. PMID: 37578744 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous
